Key Highlights

  • Total revenues rose 10.4% to USD 1,243.0 million, with product sales up 12.4% to USD 1,196.5 million.
  • Acquired in-process Research and Development expense was USD 754.2 million, against USD 42.5 million a year earlier.
  • The net loss was USD 483.4 million, or USD 7.48 per share, versus Net Income of USD 251.4 million.
  • Selling, general and administrative expense fell to USD 407.9 million from USD 530.6 million, which included litigation settlements.

Quarter in Numbers

Jazz Pharmaceuticals plc (NASDAQ:JAZZ), a biopharmaceutical company with sleep medicine, oncology and epilepsy products, reported third-quarter 2026 total revenues of USD 1,243.0 million versus USD 1,126.1 million. Product sales were USD 1,196.5 million versus USD 1,064.4 million, and royalties and contract revenues fell to USD 46.5 million from USD 61.7 million. The company increased its 2026 Revenue guidance during the quarter.

Cost of product sales fell to USD 110.6 million from USD 128.9 million, mainly because the inventory Fair Value step-up was fully recognized in the second quarter of 2026, partly offset by higher Royalty expense. Research and development expense rose to USD 211.9 million from USD 198.2 million, and intangible asset amortization was USD 171.8 million versus USD 168.4 million.

Why the Quarter Shows a Loss

Acquired in-process research and development expense jumped to USD 754.2 million from USD 42.5 million. The company completed the Acquisition of Actio Biosciences during the quarter, and management described it as an Investment in future sources of growth. Total operating expenses were USD 1,656.4 million versus USD 1,068.6 million, so the loss from operations was USD 413.4 million versus income of USD 57.5 million. Interest expense, net, was USD 45.5 million, and income tax expense was USD 24.5 million, compared with a tax benefit of USD 242.4 million a year earlier. The net loss was USD 483.4 million, or USD 7.48 per share, on 64.7 million shares, versus net income of USD 251.4 million, or USD 4.08 per diluted share.

By our calculation, excluding the acquired research charge the quarter would have shown income from operations of roughly USD 340.8 million.

Selling Costs and Product Detail

Selling, general and administrative expense fell to USD 407.9 million from USD 530.6 million, mainly because the prior-year quarter included an Avadel litigation settlement of USD 90.0 million and a Xyrem antitrust litigation settlement of USD 61.5 million. Exiting the quarter there were about 17,550 active patients taking Xywav, including about 11,375 with narcolepsy and about 6,175 with idiopathic hypersomnia. Management said Xywav held the number one branded oxybate position for narcolepsy by revenue in the quarter and remains the only FDA-approved therapy for idiopathic hypersomnia.

Epidiolex product sales decreased on higher gross-to-net deductions, because a reserve release in the prior-year period was partly offset by a higher average selling price. Defitelio sales increased on Volume and price, and Vyxeos sales decreased on a lower average selling price due to regional mix.

For the nine months, total revenues were USD 3,520.2 million versus USD 3,069.6 million, and net income was USD 2.5 million versus a net loss of USD 559.6 million. The nine-month figures include a USD 122.8 million gain on the sale of a priority review voucher and USD 831.2 million of acquired in-process research and development, versus USD 947.9 million a year earlier.

On the call, management said the arrival of orexin 2 receptor agonists could extend the time some new patients take to start therapy, but that it expects Xywav to remain a foundational therapy, and that payer discussions for 2027 are well underway.

Indicators for Reimbursement and Pipeline

Items to track include Xywav patient counts, Epidiolex gross-to-net trends, orexin competition, spending on acquired programs and the guidance raise relative to the loss in the quarter.